Inside Precision Medicine October 23, 2024
The U.S. National Institutes of Health has launched a unique portfolio of biomarker-driven precision medicine clinical trials, known as myeloMATCH, that will test new treatments for patients with myeloid cancers.
The patients will be enrolled in the trial from diagnosis through multiple stages of their treatment journey.
“MyeloMATCH provides a portfolio of biomarker-driven treatment trials that adult patients newly diagnosed with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) will enroll to sequentially over their entire treatment journey,” said co-chair of myeloMATCH’s senior science council Harry Erba, MD, PhD of Duke University School of Medicine. “At each step along that journey, the goal is to continually reduce the patient’s tumor burden, to target residual disease more effectively, and ultimately cure...
Today's Sponsors
Today's Sponsor
